In 2012, Stephen P. MacMillan earned $208.33K in total compensation at Stryker, primarily from $208.33K salary. Most recently acquired 39,677 shares in Nov 2024. Currently holds stock worth $108.06M. Has donated $87.50M in stock to charitable causes. Led Stryker as CEO for 7 years.
Compensation History
Annual executive compensation data for Stephen P. MacMillan, including salary, bonuses, and stock awards.
Year
2012
Total Compensation
$208.33K
Salary
$208.33K
Bonus
$0.00
Other
$0.00
Salary
$208.33KBoard Justification
The compensation philosophy is to align executive compensation with company performance and shareholder interests, focusing on attracting and retaining top talent.
Bonus
$0.00Board Justification
No bonus was awarded for 2012 due to resignation before the bonus plan was finalized.
Other Compensation
$0.00Board Justification
No other compensation was reported for 2012.
Restricted Stock
Board Justification
No stock awards were granted in 2012 due to resignation on February 8, 2012.
Performance Metrics
Performance metrics for the bonus plan were not applicable due to resignation.
Stephen P. MacMillan
Ex-CEO of Stryker
Education
Bachelor of Arts in Economics from Davidson College; graduate of Harvard Business School Advanced Management Program.
Field of Expertise
Business & Management
Sector of Economy
Healthcare
Born
December 10, 1963 - 61 years ago
CEO of Stryker for
7 years 8 months (Jan 2005 - Sep 2012)
Previous Experience
Sector Vice President, Global Specialty Operations for Pharmacia Corporation, and President of Johnson & Johnson-Merck Consumer Pharmaceuticals.
Holdings
Track Stephen P. MacMillan's stock holdings and portfolio value over time.
Total Stock Sold
$58.81M
$58.81M
1,041,528 HOLX shares
What if they kept their stock?
If Stephen P. MacMillan didn't sell their stock, today they would have:
Extra HOLX1,041,528 shares worth $78.08M.
This is 32.77% and $19.27M more than what they got when they sold the stock.
Charitable Transactions
1,167,079 shares
HOLX
Recent Charitable Transactions
57,875 shares
HOLX
May 23, 2024
Charity
24,000 shares
HOLX
Apr 19, 2024
Charity
1,064,954 shares
HOLX
Aug 30, 2023
Charity
20,250 shares
HOLX
Sep 25, 2021
Charity
Insider Trading
Stephen P. MacMillan's recent stock transactions, purchases, and sales filed with the SEC.
39,677 shares
HOLX
Nov 7, 2024
Received
118,560 shares
HOLX
Nov 5, 2024
Received
$3.59M
HOLX at $81.45/share
Jul 30, 2024
Sale
$294.22K
HOLX at $80.13/share
Jul 17, 2024
Sale
57,875 shares
HOLX
May 23, 2024
Charity
24,000 shares
HOLX
Apr 19, 2024
Charity
$3.36M
HOLX at $70.41/share
Nov 29, 2023
Sale
40,832 shares
HOLX
Nov 14, 2023
Received
24,133 shares
HOLX
Nov 6, 2023
Received
1,064,954 shares
HOLX
Aug 30, 2023
Charity
Rivals
Compare Stephen P. MacMillan with competitor CEOs and industry peers.
Javier J. Rodriguez
CEO of DaVita
2022 Compensation
Stock
$0.00
Salary
$1.20M
Bonus
$0.00
Other
$610.78K
Total Holdings
$140.33M
Geoffrey S. Martha
CEO of Medtronic
2023 Compensation
Stock
$0.00
Salary
$1.35M
Bonus
$1.91M
Other
$305.50K
Total Holdings
$89.72K
Steven H. Collis
CEO of Cencora
2023 Compensation
Stock
$0.00
Salary
$1.40M
Bonus
$3.23M
Other
$379.52K
Total Holdings
$242.12M
Gary S. Guthart
CEO of Intuitive Surgical
2022 Compensation
Stock
$5.79M
Salary
$873.08K
Bonus
$1.36M
Other
$1.50K
Total Holdings
$11.23M
Jason M. Hollar
CEO of Cardinal Health
2022 Compensation
Stock
$300.00K
Salary
$1.20M
Bonus
$500.00K
Other
$200.00K
Total Holdings
$728.86K
Michael F. Mahoney
CEO of Boston Scientific
2024 Compensation
Stock
$19.49M
Salary
$1.40M
Bonus
$3.74M
Other
$193.39K
Total Holdings
$42.71M